RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The...
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The...
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The U.S. Participating In The Study
RenovoRx宣佈，位於紐約海德公園的Northwell Health癌症研究所正在招募局部晚期胰腺癌患者，參與公司的III期TiGeR-PaC臨床試驗；NHCI加入了美國各地參與該研究的著名臨床地點。
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Northwell Health癌症研究所是最近加入TIGeR-PaC研究的臨床地點，RenovoRx旨在於2025年上半年達到完全患者招募。
Phase III Clinical Trial is Evaluating the TAMP (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
III期臨床試驗正在評估TAMP（經動脈微灌注）治療平台用於治療局部晚期胰腺癌。
LOS ALTOS, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, announced today that the Northwell Health Cancer Institute ("NHCI") in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. NHCI joins esteemed clinical sites throughout the United States participating in the study.
加利福尼亞州洛斯阿爾託斯，2024年11月20日（全球新聞通訊）—— RenovoRx, Inc.（"RenovoRx"或"公司"）（納斯達克:RNXT），一家開發新型靶向腫瘤治療並提供RenovoCath——一種新型的FDA批准的局部藥物輸送平台的生命科學公司，今天宣佈，位於紐約海德公園的Northwell Health癌症研究所（"NHCI"）正在招募局部晚期胰腺癌（LAPC）患者，參與公司正在進行的關鍵III期TIGeR-PaC臨床試驗。NHCI加入了美國各地參與該研究的著名臨床地點。
